These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 17389259)

  • 21. Serum uric acid/creatinine ratio and free androgen index are synergistically associated with increased risk of polycystic ovary syndrome in obese women.
    El-Eshmawy MM; Ibrahim A; Bahriz R; Shams-Eldin N; Mahsoub N
    BMC Endocr Disord; 2022 Dec; 22(1):315. PubMed ID: 36514085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents.
    Glueck CJ; Morrison JA; Friedman LA; Goldenberg N; Stroop DM; Wang P
    Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Office blood pressure, ambulatory blood pressure monitoring, and echocardiographic abnormalities in women with polycystic ovary syndrome: role of obesity and androgen excess.
    Luque-Ramírez M; Martí D; Fernández-Durán E; Alpañés M; Álvarez-Blasco F; Escobar-Morreale HF
    Hypertension; 2014 Mar; 63(3):624-9. PubMed ID: 24324038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.
    Diamanti-Kandarakis E; Kouli CR; Bergiele AT; Filandra FA; Tsianateli TC; Spina GG; Zapanti ED; Bartzis MI
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4006-11. PubMed ID: 10566641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum HLA-G levels in women with polycystic ovary syndrome.
    Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
    Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimüllerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome.
    Feldman RA; O'Neill K; Butts SF; Dokras A
    Fertil Steril; 2017 Jan; 107(1):276-281. PubMed ID: 27842995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.
    Pepene CE; Ilie IR; Marian I; Duncea I
    Eur J Endocrinol; 2011 Jan; 164(1):61-8. PubMed ID: 20974706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.
    Rajkhowa M; Neary RH; Kumpatla P; Game FL; Jones PW; Obhrai MS; Clayton RN
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3389-94. PubMed ID: 9329374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
    Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
    Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
    Verit FF
    Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperinsulinemia and obese phenotype differently influence blood pressure in young normotensive patients with polycystic ovary syndrome.
    Mioni R; Cà AD; Turra J; Azzolini S; Xamin N; Bleve L; Maffei P; Vettor R; Fallo F
    Endocrine; 2017 Feb; 55(2):625-634. PubMed ID: 27142411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vigorous exercise is associated with superior metabolic profiles in polycystic ovary syndrome independent of total exercise expenditure.
    Greenwood EA; Noel MW; Kao CN; Shinkai K; Pasch LA; Cedars MI; Huddleston HG
    Fertil Steril; 2016 Feb; 105(2):486-93. PubMed ID: 26551442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters.
    Sieminska L; Marek B; Kos-Kudla B; Niedziolka D; Kajdaniuk D; Nowak M; Glogowska-Szelag J
    J Endocrinol Invest; 2004 Jun; 27(6):528-34. PubMed ID: 15717649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study.
    Pinola P; Piltonen TT; Puurunen J; Vanky E; Sundström-Poromaa I; Stener-Victorin E; Ruokonen A; Puukka K; Tapanainen JS; Morin-Papunen LC
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3400-7. PubMed ID: 26192874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome phenotype.
    Xita N; Georgiou I; Lazaros L; Psofaki V; Kolios G; Tsatsoulis A
    Eur J Endocrinol; 2008 Jun; 158(6):861-5. PubMed ID: 18505907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between retinol-binding protein 4 levels, insulin resistance, androgen hormones and polycystic ovary syndrome.
    Mellati AA; Sharifi F; Sajadinejad M; Sohrabi D; Mazloomzadeh S
    Scand J Clin Lab Invest; 2012 Feb; 72(1):39-44. PubMed ID: 22023042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.